Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 7/20 | 0.65 |
| ▸ | DPP4 | P27487 | 3/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201978 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL124005 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL7870187 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL20011747 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL199332 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL25396765 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL8512122 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL197989 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| Hydrochloric Acid SCHEMBL18094024 | 0.98 | HDAC2 (0.63) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| Hydrochloric Acid SCHEMBL10461198 | 0.98 | HDAC2 (0.63) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271224-A | Preparation method of (2S, 4S) -4-cyclohexyl-L-proline | 浙江华海药业股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-114516825-A | Method for preparing (2S,4S) -4-cyclohexyl-L-proline | 浙江华海药业股份有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-111303002-B | Method for treating fosinopril intermediate mother liquor | 浙江工业大学 | 2021-05-07 | — | — | CN | claimed |
| CN-111303002-A | Method for treating fosinopril intermediate mother liquor | 浙江工业大学 | 2020-06-19 | — | — | CN | claimed |
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| EP-2922559-B1 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2018-10-10 | — | — | EP | claimed |
| US-10005829-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | claimed |
| CN-105007928-B | For treating the synthesizing linear APELIN analogies of heart failure | 诺华股份有限公司 | 2018-03-20 | — | — | CN | claimed |
| EP-3154568-A1 | NON-CANONICAL INSULINS AND THEIR USES | California Institute of Technology (US) | 2017-04-19 | — | — | EP | claimed |
| US-20160076058-A1 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | GENOMATICA, INC. | 2016-03-17 | — | — | US | claimed |
| EP-1062222-A1 | SERINE PEPTIDASE MODULATORS | Fondatech Benelux N.V. (BE) | 2000-12-27 | — | — | EP | claimed |
| US-6090786-A | HALOPYRROLE AMIDATED AMINO ACID USEFUL FOR INHIBITING SERINE PROTEASE ACTIVITY | FONDATECH BENELUX N.V. (BE) | 2000-07-18 | — | — | US | claimed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | claimed |
| EP-0764151-A2 | PURIFICATION OF SERINE PROTEASE AND SYNTHETIC INHIBITORS THEREOF | UNIVERSITAIRE INSTELLING ANTWERPEN (BE) | 1997-03-26 | — | — | EP | claimed |
| EP-0732399-A2 | Chymotrypsin-like proteases and their inhibitors | CEPHALON, INC. (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1995034538-A2 | PURIFICATION OF SERINE PROTEASES AND SYNTHETIC INHIBITORS THEREOF | UNIVERSITAIRE INSTELLING ANTWERPEN (BE) | 1995-12-21 | — | — | WO | claimed |
| EP-0518955-A4 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | — | 1993-09-22 | — | — | EP | claimed |
| EP-0518955-A1 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | CEPHALON, INC. (US) | 1992-12-23 | — | — | EP | claimed |
| WO-1991013904-A1 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | CEPHALON, INC. (US) | 1991-09-19 | — | — | WO | claimed |
| US-4912231-A | Reacting a proline derivative with an aromatic nucleophile in presence of a Lewis acid catalyst | E. R. SQUIBB & SONS, INC. (US) | 1990-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005829-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | APLNR, AP3B1, FABP3 | HDAC2 4410/4885DPP4 165/4885AKR1C3 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.